

Global Adalimumab (Humira) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GDF2AB773D39EN.html>

Date: June 2023

Pages: 100

Price: US\$ 3,480.00 (Single User License)

ID: GDF2AB773D39EN

Abstracts

According to our (Global Info Research) latest study, the global Adalimumab (Humira) and Biosimilar market size was valued at USD 23070 million in 2022 and is forecast to a readjusted size of USD 16210 million by 2029 with a CAGR of -4.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

This report is a detailed and comprehensive analysis for global Adalimumab (Humira) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market

share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Adalimumab (Humira) and Biosimilar market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab (Humira) and Biosimilar market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab (Humira) and Biosimilar market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Adalimumab (Humira) and Biosimilar market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Adalimumab (Humira) and Biosimilar

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals and Amgen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Adalimumab (Humira) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Syringe

Pen

Market segment by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn's Disease

Other

Major players covered

AbbVie

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Amgen

Boehringer Ingelheim

Novartis

Samsung Bioepis

Viartis

Pfizer

Fresenius Kabi

Coherus

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Adalimumab (Humira) and Biosimilar product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Adalimumab (Humira) and Biosimilar, with price, sales, revenue and global market share of Adalimumab (Humira) and Biosimilar from 2018 to 2023.

Chapter 3, the Adalimumab (Humira) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed

emphatically by landscape contrast.

Chapter 4, the Adalimumab (Humira) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Adalimumab (Humira) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab (Humira) and Biosimilar.

Chapter 14 and 15, to describe Adalimumab (Humira) and Biosimilar sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Syringe
 - 1.3.3 Pen
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Ankylosing Spondylitis
 - 1.4.3 Rheumatoid Arthritis
 - 1.4.4 Crohn's Disease
 - 1.4.5 Other
- 1.5 Global Adalimumab (Humira) and Biosimilar Market Size & Forecast
 - 1.5.1 Global Adalimumab (Humira) and Biosimilar Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029)
 - 1.5.3 Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 AbbVie
 - 2.1.1 AbbVie Details
 - 2.1.2 AbbVie Major Business
 - 2.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
 - 2.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 AbbVie Recent Developments/Updates
- 2.2 Eisai
 - 2.2.1 Eisai Details
 - 2.2.2 Eisai Major Business
 - 2.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
 - 2.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.2.5 Eisai Recent Developments/Updates
- 2.3 Cadila Healthcare
 - 2.3.1 Cadila Healthcare Details
 - 2.3.2 Cadila Healthcare Major Business
 - 2.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
 - 2.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 Cadila Healthcare Recent Developments/Updates
- 2.4 Torrent Pharmaceuticals
 - 2.4.1 Torrent Pharmaceuticals Details
 - 2.4.2 Torrent Pharmaceuticals Major Business
 - 2.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
 - 2.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
- 2.5 Amgen
 - 2.5.1 Amgen Details
 - 2.5.2 Amgen Major Business
 - 2.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
 - 2.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 Amgen Recent Developments/Updates
- 2.6 Boehringer Ingelheim
 - 2.6.1 Boehringer Ingelheim Details
 - 2.6.2 Boehringer Ingelheim Major Business
 - 2.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
 - 2.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Boehringer Ingelheim Recent Developments/Updates
- 2.7 Novartis
 - 2.7.1 Novartis Details
 - 2.7.2 Novartis Major Business
 - 2.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
 - 2.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Novartis Recent Developments/Updates
- 2.8 Samsung Bioepis
 - 2.8.1 Samsung Bioepis Details

- 2.8.2 Samsung Bioepis Major Business
- 2.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
- 2.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.8.5 Samsung Bioepis Recent Developments/Updates
- 2.9 Viatris
 - 2.9.1 Viatris Details
 - 2.9.2 Viatris Major Business
 - 2.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
 - 2.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Viatris Recent Developments/Updates
- 2.10 Pfizer
 - 2.10.1 Pfizer Details
 - 2.10.2 Pfizer Major Business
 - 2.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
 - 2.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Pfizer Recent Developments/Updates
- 2.11 Fresenius Kabi
 - 2.11.1 Fresenius Kabi Details
 - 2.11.2 Fresenius Kabi Major Business
 - 2.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
 - 2.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Fresenius Kabi Recent Developments/Updates
- 2.12 Coherus
 - 2.12.1 Coherus Details
 - 2.12.2 Coherus Major Business
 - 2.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
 - 2.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.12.5 Coherus Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ADALIMUMAB (HUMIRA) AND BIOSIMILAR BY MANUFACTURER

- 3.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023)

- 3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023)
- 3.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
 - 3.4.1 Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue (\$MM) and Market Share (%): 2022
 - 3.4.2 Top 3 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
 - 3.4.2 Top 6 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
- 3.5 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
 - 3.5.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
 - 3.5.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
 - 3.5.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region
 - 4.1.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
 - 4.1.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
 - 4.1.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
- 4.2 North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
- 4.3 Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
- 4.4 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
- 4.5 South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
- 4.6 Middle East and Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
- 5.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2029)

5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

6.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2029)

6.3 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)

7.2 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

7.3 North America Adalimumab (Humira) and Biosimilar Market Size by Country

7.3.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)

7.3.2 North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)

8.2 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

8.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country

8.3.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)

8.3.2 Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

8.3.4 France Market Size and Forecast (2018-2029)

8.3.5 United Kingdom Market Size and Forecast (2018-2029)

8.3.6 Russia Market Size and Forecast (2018-2029)

8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)

9.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

9.3 Asia-Pacific Adalimumab (Humira) and Biosimilar Market Size by Region

9.3.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)

9.3.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)

9.3.3 China Market Size and Forecast (2018-2029)

9.3.4 Japan Market Size and Forecast (2018-2029)

9.3.5 Korea Market Size and Forecast (2018-2029)

9.3.6 India Market Size and Forecast (2018-2029)

9.3.7 Southeast Asia Market Size and Forecast (2018-2029)

9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)

10.2 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

10.3 South America Adalimumab (Humira) and Biosimilar Market Size by Country

10.3.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)

10.3.2 South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)

10.3.3 Brazil Market Size and Forecast (2018-2029)

10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)

11.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)

11.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Market Size by Country

11.3.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)

11.3.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)

11.3.3 Turkey Market Size and Forecast (2018-2029)

11.3.4 Egypt Market Size and Forecast (2018-2029)

11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)

11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Adalimumab (Humira) and Biosimilar Market Drivers

12.2 Adalimumab (Humira) and Biosimilar Market Restraints

12.3 Adalimumab (Humira) and Biosimilar Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

12.5 Influence of COVID-19 and Russia-Ukraine War

12.5.1 Influence of COVID-19

12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Adalimumab (Humira) and Biosimilar and Key Manufacturers

13.2 Manufacturing Costs Percentage of Adalimumab (Humira) and Biosimilar

13.3 Adalimumab (Humira) and Biosimilar Production Process

13.4 Adalimumab (Humira) and Biosimilar Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Adalimumab (Humira) and Biosimilar Typical Distributors

14.3 Adalimumab (Humira) and Biosimilar Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. AbbVie Basic Information, Manufacturing Base and Competitors

Table 4. AbbVie Major Business

Table 5. AbbVie Adalimumab (Humira) and Biosimilar Product and Services

Table 6. AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. AbbVie Recent Developments/Updates

Table 8. Eisai Basic Information, Manufacturing Base and Competitors

Table 9. Eisai Major Business

Table 10. Eisai Adalimumab (Humira) and Biosimilar Product and Services

Table 11. Eisai Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Eisai Recent Developments/Updates

Table 13. Cadila Healthcare Basic Information, Manufacturing Base and Competitors

Table 14. Cadila Healthcare Major Business

Table 15. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services

Table 16. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Cadila Healthcare Recent Developments/Updates

Table 18. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 19. Torrent Pharmaceuticals Major Business

Table 20. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services

Table 21. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Torrent Pharmaceuticals Recent Developments/Updates

Table 23. Amgen Basic Information, Manufacturing Base and Competitors

Table 24. Amgen Major Business

Table 25. Amgen Adalimumab (Humira) and Biosimilar Product and Services

Table 26. Amgen Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 27. Amgen Recent Developments/Updates

Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors

Table 29. Boehringer Ingelheim Major Business

Table 30. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services

Table 31. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 32. Boehringer Ingelheim Recent Developments/Updates

Table 33. Novartis Basic Information, Manufacturing Base and Competitors

Table 34. Novartis Major Business

Table 35. Novartis Adalimumab (Humira) and Biosimilar Product and Services

Table 36. Novartis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 37. Novartis Recent Developments/Updates

Table 38. Samsung Bioepis Basic Information, Manufacturing Base and Competitors

Table 39. Samsung Bioepis Major Business

Table 40. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services

Table 41. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 42. Samsung Bioepis Recent Developments/Updates

Table 43. Viartis Basic Information, Manufacturing Base and Competitors

Table 44. Viartis Major Business

Table 45. Viartis Adalimumab (Humira) and Biosimilar Product and Services

Table 46. Viartis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 47. Viartis Recent Developments/Updates

Table 48. Pfizer Basic Information, Manufacturing Base and Competitors

Table 49. Pfizer Major Business

Table 50. Pfizer Adalimumab (Humira) and Biosimilar Product and Services

Table 51. Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 52. Pfizer Recent Developments/Updates

Table 53. Fresenius Kabi Basic Information, Manufacturing Base and Competitors

Table 54. Fresenius Kabi Major Business

Table 55. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services

Table 56. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 57. Fresenius Kabi Recent Developments/Updates

Table 58. Coherus Basic Information, Manufacturing Base and Competitors

Table 59. Coherus Major Business

Table 60. Coherus Adalimumab (Humira) and Biosimilar Product and Services

Table 61. Coherus Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 62. Coherus Recent Developments/Updates

Table 63. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 64. Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)

Table 65. Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 66. Market Position of Manufacturers in Adalimumab (Humira) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 67. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer

Table 68. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint

Table 69. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint

Table 70. Adalimumab (Humira) and Biosimilar New Market Entrants and Barriers to Market Entry

Table 71. Adalimumab (Humira) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations

Table 72. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 73. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 74. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 75. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 76. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US\$/Unit)

Table 77. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US\$/Unit)

Table 78. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 79. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 80. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)

Table 81. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)

Table 82. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US\$/Unit)

Table 83. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US\$/Unit)

Table 84. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 85. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 86. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)

Table 87. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)

Table 88. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US\$/Unit)

Table 89. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US\$/Unit)

Table 90. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 91. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 92. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 93. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 94. North America Adalimumab (Humira) and Biosimilar Sales Quantity by

Country (2018-2023) & (K Units)

Table 95. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 96. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 97. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 98. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 99. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 100. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 101. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 102. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 103. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 104. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 105. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 106. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 107. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 108. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 109. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 110. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 111. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 112. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 113. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 114. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 115. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 116. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 117. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 118. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 119. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 120. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 121. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 122. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 123. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 124. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 125. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 126. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 127. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 128. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 129. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 130. Adalimumab (Humira) and Biosimilar Raw Material

Table 131. Key Manufacturers of Adalimumab (Humira) and Biosimilar Raw Materials

Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors

Table 133. Adalimumab (Humira) and Biosimilar Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Adalimumab (Humira) and Biosimilar Picture
- Figure 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type in 2022
- Figure 4. Syringe Examples
- Figure 5. Pen Examples
- Figure 6. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Figure 7. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application in 2022
- Figure 8. Ankylosing Spondylitis Examples
- Figure 9. Rheumatoid Arthritis Examples
- Figure 10. Crohn's Disease Examples
- Figure 11. Other Examples
- Figure 12. Global Adalimumab (Humira) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 13. Global Adalimumab (Humira) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029) & (K Units)
- Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US\$/Unit)
- Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
- Figure 17. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
- Figure 18. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021
- Figure 19. Top 3 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
- Figure 20. Top 6 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
- Figure 21. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 22. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 23. North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 24. Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 25. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 26. South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 27. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 28. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 29. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type (2018-2029)

Figure 30. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US\$/Unit)

Figure 31. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 32. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application (2018-2029)

Figure 33. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US\$/Unit)

Figure 34. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 35. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 36. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 37. North America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 38. United States Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Canada Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Mexico Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 41. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by

Type (2018-2029)

Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 44. Europe Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 45. Germany Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. France Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. United Kingdom Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Russia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Italy Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 51. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 52. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 53. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 54. China Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Japan Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. Korea Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. India Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Southeast Asia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Australia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

- Figure 61. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
- Figure 62. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
- Figure 63. South America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
- Figure 64. Brazil Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 65. Argentina Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 66. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
- Figure 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
- Figure 68. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
- Figure 69. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
- Figure 70. Turkey Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 71. Egypt Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 72. Saudi Arabia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 73. South Africa Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
- Figure 74. Adalimumab (Humira) and Biosimilar Market Drivers
- Figure 75. Adalimumab (Humira) and Biosimilar Market Restraints
- Figure 76. Adalimumab (Humira) and Biosimilar Market Trends
- Figure 77. Porters Five Forces Analysis
- Figure 78. Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar in 2022
- Figure 79. Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar
- Figure 80. Adalimumab (Humira) and Biosimilar Industrial Chain
- Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
- Figure 82. Direct Channel Pros & Cons
- Figure 83. Indirect Channel Pros & Cons
- Figure 84. Methodology
- Figure 85. Research Process and Data Source

I would like to order

Product name: Global Adalimumab (Humira) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GDF2AB773D39EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDF2AB773D39EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

